Efficacy and safety of rituximab in the treatment of primary central nervous system lymphoma: A meta-analysis and systematic review of 1,388 patients
Lichaoyue Sun, Wenshu Li, Wei Chen, Chunxing Li, Zhao Ren, Qing Xie, Dongxiao Wang · 2026
Read Efficacy and safety of rituximab in the treatment of primary central nervous system lymphoma: A meta-analysis and systematic review of 1,388 patients by Lichaoyue Sun, Wenshu Li, Wei Chen, Chunxing Li, Zhao Ren, Qing Xie, Dongxiao Wang (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13573275.txt.
Description
Lichaoyue Sun and co-authors pool trial data on a targeted antibody drug for a rare brain lymphoma. Their 2026 review covers primary central nervous system lymphoma, a fast-growing cancer with poor outlook. The value of adding rituximab to standard chemo has stayed in dispute.
The search spans four major databases up to May 2025 with no language bar. Fifteen studies with 1,388 patients enter the pooled sums. Patients on the added drug showed far better three-year survival odds than controls. Pooled hazard sums also favor the drug arm for both survival and time without growth. The review weighs side effects alongside gains. The authors judge the add-on a clear benefit for newly diagnosed patients.
Catalog record
| CREATOR | Lichaoyue Sun, Wenshu Li, Wei Chen, Chunxing Li, Zhao Ren, Qing Xie, Dongxiao Wang |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 34 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |